Advertisement

IgG4-Related Sclerosing Cholangitis in America

  • Sajan Jiv Singh Nagpal
  • Suresh Chari
Chapter

Abstract

Since its first description in the 1960s from the United States, IgG4-SC has been increasingly recognized and reported from around the world. It is the most common extrapancreatic manifestation of type 1 autoimmune pancreatitis and is possibly associated with an accelerated development of secondary biliary cirrhosis if diagnosis is delayed. Obstructive jaundice and constitutional symptoms are the main presenting symptoms, similar to hilar cholangiocarcinoma and primary sclerosing cholangitis, which are the most important differential diagnoses of IgG4-SC. Endoscopy is critical to rule out malignancy. While steroids are the mainstay of initial treatment, and most patients respond rapidly, there is a very high likelihood of relapse, especially in patients with proximal biliary strictures. Initiation of immunomodulators or rituximab may be required to maintain long-term remission. In this chapter we will describe the epidemiology, diagnosis, clinical presentation, and management of IgG4-SC based on studies primarily from the United States.

References

  1. 1.
    Bartholomew LG, Cain JC, Woolner LB, Utz DC, Ferris DO. Sclerosing cholangitis: its possible association with Riedel’s struma and fibrous retroperitonitis. Report of two cases. N Engl J Med. 1963;269:8–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Comings DE, Skubi KB, Van Eyes J, Motulsky AG. Familial multifocal fibrosclerosis. Findings suggesting that retroperitoneal fibrosis, mediastinal fibrosis, sclerosing cholangitis, Riedel's thyroiditis, and pseudotumor of the orbit may be different manifestations of a single disease. Ann Intern Med. 1967;66(5):884–92.CrossRefPubMedGoogle Scholar
  3. 3.
    Myers RN, Cooper JH, Padis N. Primary sclerosing cholangitis. Complete gross and histologic reversal after long-term steroid therapy. Am J Gastroenterol. 1970;53(6):527–38.PubMedGoogle Scholar
  4. 4.
    Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease. Am J Gastroenterol. 2003;98(12):2811–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol. 2011;23(1):57–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–78.CrossRefPubMedGoogle Scholar
  8. 8.
    Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Hamano H, Arakura N, Muraki T, Ozaki Y, Kiyosawa K, Kawa S. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol. 2006;41(12):1197–205.CrossRefPubMedGoogle Scholar
  10. 10.
    Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Graham RP, Smyrk TC, Chari ST, Takahashi N, Zhang L. Isolated IgG4-related sclerosing cholangitis: a report of 9 cases. Hum Pathol. 2014;45(8):1722–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Kanno A, Masamune A, Okazaki K, Kamisawa T, Kawa S, Nishimori I, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas. 2015;44(4):535–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Plaza JA, Garrity JA, Dogan A, Ananthamurthy A, Witzig TE, Salomao DR. Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease. Arch Ophthalmol. 2011;129(4):421–8.CrossRefPubMedGoogle Scholar
  14. 14.
    de Buy Wenniger LJM, Culver EL, Beuers U. Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology. 2014;60(4):1453–4.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chari ST, Takahashi N, Levy MJ, Smyrk TC, Clain JE, Pearson RK, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol. 2009;7(10):1097–103.CrossRefPubMedGoogle Scholar
  16. 16.
    Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, Chapman MH, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109(10):1675–83.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Buijs J, Cahen DL, van Heerde MJ, Rauws EA, de Buy Wenniger LJ, Hansen BE, et al. The long-term impact of autoimmune pancreatitis on pancreatic function, quality of life, and life expectancy. Pancreas. 2015;44(7):1065–71.CrossRefPubMedGoogle Scholar
  18. 18.
    Shiokawa M, Kodama Y, Yoshimura K, Kawanami C, Mimura J, Yamashita Y, et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol. 2013;108(4):610–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis. 2015;74(1):14–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Bjornsson E, Chari S, Silveira M, Gossard A, Takahashi N, Smyrk T, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18(3):198–205.CrossRefPubMedGoogle Scholar
  21. 21.
    Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol. 2011;23(1):108–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Culver EL, Vermeulen E, Makuch M, van Leeuwen A, Sadler R, Cargill T, et al. Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease. Ann Rheum Dis. 2015;74(5):944–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tokala A, Khalili K, Menezes R, Hirschfield G, Jhaveri KS. Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. AJR Am J Roentgenol. 2014;202(3):536–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Vosskuhl K, Negm AA, Framke T, Weismuller T, Manns MP, Wedemeyer H, et al. Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy. 2012;44(1):48–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Kalaitzakis E, Levy M, Kamisawa T, Johnson GJ, Baron TH, Topazian MD, et al. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011;9(9):800–3.e2.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Topazian M, Witzig TE, Smyrk TC, Pulido JS, Levy MJ, Kamath PS, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008;6(3):364–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2019

Authors and Affiliations

  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations